BTIG Research Begins Coverage on Solventum (NYSE:SOLV)

Equities researchers at BTIG Research initiated coverage on shares of Solventum (NYSE:SOLV) in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm set a “neutral” rating on the stock.

A number of other research firms have also recently commented on SOLV. Bank of America reduced their price target on Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a report on Tuesday, June 25th. The Goldman Sachs Group lifted their target price on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Argus assumed coverage on Solventum in a research note on Monday, June 24th. They issued a “hold” rating on the stock. Wells Fargo & Company reduced their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. Finally, Morgan Stanley decreased their price objective on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $58.25.

Solventum Trading Up 0.9 %

Shares of Solventum stock opened at $66.20 on Thursday. Solventum has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90. The business’s 50 day moving average is $56.95.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.10. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. The firm’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts expect that Solventum will post 6.38 EPS for the current year.

Institutional Investors Weigh In On Solventum

Institutional investors have recently modified their holdings of the business. Deseret Mutual Benefit Administrators bought a new stake in shares of Solventum in the second quarter valued at about $25,000. Hollencrest Capital Management bought a new stake in shares of Solventum in the second quarter valued at about $25,000. Partnership Wealth Management LLC bought a new stake in shares of Solventum in the second quarter valued at about $26,000. Richard W. Paul & Associates LLC bought a new stake in shares of Solventum in the second quarter valued at about $26,000. Finally, Family Firm Inc. bought a new stake in shares of Solventum in the second quarter valued at about $26,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.